 Jennifer Jung
Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 8 | 2026 | 490 | 2.050 |
Why?
| | Retinopathy of Prematurity | 6 | 2026 | 181 | 1.770 |
Why?
| | Porencephaly | 2 | 2019 | 6 | 1.200 |
Why?
| | Cataract | 3 | 2019 | 238 | 1.080 |
Why?
| | Laser Coagulation | 2 | 2026 | 80 | 1.020 |
Why?
| | Pars Planitis | 1 | 2026 | 6 | 0.960 |
Why?
| | Tertiary Care Centers | 2 | 2026 | 195 | 0.920 |
Why?
| | Glucocorticoids | 3 | 2026 | 532 | 0.900 |
Why?
| | Angiogenesis Inhibitors | 1 | 2026 | 239 | 0.830 |
Why?
| | Ophthalmology | 2 | 2026 | 120 | 0.740 |
Why?
| | Collagen Type IV | 2 | 2019 | 27 | 0.740 |
Why?
| | Vigabatrin | 1 | 2021 | 19 | 0.670 |
Why?
| | Keratoconus | 3 | 2025 | 23 | 0.650 |
Why?
| | Abnormalities, Multiple | 2 | 2019 | 199 | 0.640 |
Why?
| | Birth Weight | 4 | 2024 | 517 | 0.630 |
Why?
| | Anticonvulsants | 1 | 2021 | 246 | 0.560 |
Why?
| | Neonatal Screening | 1 | 2017 | 179 | 0.450 |
Why?
| | Intravitreal Injections | 2 | 2026 | 71 | 0.440 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 317 | 0.430 |
Why?
| | Anesthesia, General | 2 | 2025 | 121 | 0.410 |
Why?
| | Gestational Age | 6 | 2026 | 989 | 0.400 |
Why?
| | Cornea | 2 | 2025 | 154 | 0.400 |
Why?
| | Uveitis | 2 | 2024 | 150 | 0.380 |
Why?
| | Retrospective Studies | 17 | 2026 | 17325 | 0.380 |
Why?
| | DNA | 1 | 2019 | 1437 | 0.370 |
Why?
| | Infant | 11 | 2026 | 10090 | 0.340 |
Why?
| | Mutation | 2 | 2019 | 4090 | 0.330 |
Why?
| | Corneal Topography | 3 | 2025 | 25 | 0.330 |
Why?
| | Retinal Diseases | 2 | 2025 | 101 | 0.320 |
Why?
| | Follow-Up Studies | 5 | 2026 | 5428 | 0.310 |
Why?
| | Algorithms | 1 | 2017 | 1850 | 0.290 |
Why?
| | Down Syndrome | 2 | 2025 | 525 | 0.270 |
Why?
| | Tomography | 2 | 2025 | 45 | 0.270 |
Why?
| | Fluorescein Angiography | 2 | 2026 | 189 | 0.270 |
Why?
| | Intraocular Pressure | 2 | 2026 | 330 | 0.250 |
Why?
| | Infant, Newborn | 7 | 2026 | 6464 | 0.240 |
Why?
| | Ophthalmologists | 1 | 2026 | 21 | 0.240 |
Why?
| | Child | 13 | 2026 | 22739 | 0.230 |
Why?
| | Child, Preschool | 10 | 2026 | 11868 | 0.230 |
Why?
| | Bevacizumab | 1 | 2026 | 168 | 0.220 |
Why?
| | Riboflavin | 1 | 2025 | 15 | 0.220 |
Why?
| | Corneal Stroma | 1 | 2025 | 24 | 0.220 |
Why?
| | Photochemotherapy | 1 | 2025 | 39 | 0.220 |
Why?
| | Photosensitizing Agents | 1 | 2025 | 42 | 0.210 |
Why?
| | Nephritis, Interstitial | 1 | 2024 | 11 | 0.210 |
Why?
| | Fluocinolone Acetonide | 1 | 2024 | 15 | 0.210 |
Why?
| | Patient Positioning | 1 | 2025 | 70 | 0.210 |
Why?
| | Drug Implants | 1 | 2024 | 83 | 0.210 |
Why?
| | Cross-Linking Reagents | 1 | 2025 | 206 | 0.210 |
Why?
| | Pyrimidinones | 1 | 2025 | 125 | 0.210 |
Why?
| | Diseases in Twins | 1 | 2024 | 116 | 0.210 |
Why?
| | Male | 18 | 2026 | 73003 | 0.200 |
Why?
| | Twins | 1 | 2024 | 152 | 0.200 |
Why?
| | Female | 19 | 2026 | 79035 | 0.200 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2026 | 552 | 0.190 |
Why?
| | Cranial Nerve Diseases | 2 | 2020 | 44 | 0.190 |
Why?
| | Arachnoid Cysts | 1 | 2023 | 10 | 0.190 |
Why?
| | Pyridones | 1 | 2025 | 209 | 0.190 |
Why?
| | Humans | 24 | 2026 | 145763 | 0.190 |
Why?
| | Collagen | 1 | 2025 | 457 | 0.180 |
Why?
| | Papilledema | 1 | 2023 | 44 | 0.180 |
Why?
| | Adolescent | 10 | 2026 | 22573 | 0.170 |
Why?
| | Electroretinography | 1 | 2021 | 51 | 0.170 |
Why?
| | Pontine Tegmentum | 1 | 2020 | 4 | 0.170 |
Why?
| | Cerebellar Diseases | 1 | 2020 | 27 | 0.160 |
Why?
| | Nervous System Malformations | 1 | 2020 | 46 | 0.160 |
Why?
| | Retinal Hemorrhage | 1 | 2019 | 21 | 0.150 |
Why?
| | Strabismus | 1 | 2020 | 71 | 0.150 |
Why?
| | Eye Diseases | 1 | 2020 | 97 | 0.150 |
Why?
| | Head Injuries, Closed | 1 | 2019 | 49 | 0.150 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 86 | 0.150 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2020 | 90 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 981 | 0.140 |
Why?
| | Retina | 1 | 2021 | 329 | 0.140 |
Why?
| | Vitrectomy | 1 | 2018 | 73 | 0.140 |
Why?
| | Epithelium, Corneal | 1 | 2018 | 41 | 0.140 |
Why?
| | Eye Injuries | 1 | 2018 | 53 | 0.140 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 410 | 0.130 |
Why?
| | Serum | 1 | 2018 | 58 | 0.130 |
Why?
| | Corneal Diseases | 1 | 2018 | 46 | 0.130 |
Why?
| | Attitude of Health Personnel | 1 | 2026 | 1197 | 0.130 |
Why?
| | Pedigree | 1 | 2019 | 515 | 0.130 |
Why?
| | Ophthalmic Solutions | 1 | 2018 | 82 | 0.130 |
Why?
| | Treatment Outcome | 4 | 2026 | 11793 | 0.130 |
Why?
| | Retinal Detachment | 1 | 2018 | 73 | 0.130 |
Why?
| | Developmental Disabilities | 1 | 2020 | 281 | 0.130 |
Why?
| | Infant, Premature | 2 | 2019 | 620 | 0.130 |
Why?
| | Cataract Extraction | 1 | 2018 | 120 | 0.130 |
Why?
| | Telemedicine | 1 | 2026 | 966 | 0.120 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 75 | 0.120 |
Why?
| | Hyperlipoproteinemia Type I | 1 | 2016 | 7 | 0.120 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2016 | 19 | 0.120 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 156 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2016 | 120 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 653 | 0.110 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 420 | 0.100 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 293 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 2000 | 0.090 |
Why?
| | Risk Factors | 6 | 2024 | 10917 | 0.090 |
Why?
| | Phenotype | 1 | 2019 | 3170 | 0.080 |
Why?
| | Cohort Studies | 2 | 2017 | 6032 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3752 | 0.060 |
Why?
| | Brain | 1 | 2019 | 2969 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3915 | 0.060 |
Why?
| | beta 2-Microglobulin | 1 | 2024 | 48 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2024 | 119 | 0.050 |
Why?
| | Methotrexate | 1 | 2024 | 233 | 0.050 |
Why?
| | Time Factors | 3 | 2019 | 7133 | 0.050 |
Why?
| | Rupture | 1 | 2023 | 91 | 0.050 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 270 | 0.050 |
Why?
| | Ultraviolet Rays | 1 | 2025 | 385 | 0.040 |
Why?
| | Vision Disorders | 1 | 2023 | 179 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 15 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 47 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2028 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 94 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 838 | 0.040 |
Why?
| | United States | 1 | 2017 | 16123 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 39 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2018 | 10 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2018 | 38 | 0.040 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2018 | 37 | 0.030 |
Why?
| | Young Adult | 2 | 2025 | 14251 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4556 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 244 | 0.030 |
Why?
| | Fundus Oculi | 1 | 2016 | 89 | 0.030 |
Why?
| | Lipoprotein Lipase | 1 | 2016 | 56 | 0.030 |
Why?
| | Adult | 3 | 2025 | 40872 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2410 | 0.030 |
Why?
| | Remission Induction | 1 | 2016 | 306 | 0.030 |
Why?
| | Pancreatitis | 1 | 2016 | 146 | 0.030 |
Why?
| | Child Abuse | 1 | 2019 | 553 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2026 | 6085 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5922 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 765 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2933 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2933 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4329 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8346 | 0.020 |
Why?
| | Aged | 1 | 2020 | 26215 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 36302 | 0.010 |
Why?
|
|
Jung's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|